Profile data is unavailable for this security.
About the company
XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.
- Revenue in SEK (TTM)0.00
- Net income in SEK-216.42m
- Incorporated2003
- Employees26.00
- LocationXSpray Pharma AB (publ)Rasundavagen 12SOLNA 169 67SwedenSWE
- Phone+46 87303700
- Websitehttps://xspraypharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lytix Biopharma AS | 354.13k | -68.78m | 680.66m | 6.00 | -- | 8.04 | -- | 1,922.06 | -1.08 | -1.08 | 0.0055 | 1.15 | 0.005 | -- | 0.0579 | 62,833.33 | -96.51 | -61.17 | -123.25 | -71.49 | -- | -- | -19,422.02 | -722.29 | -- | -- | 0.0301 | -- | 178.98 | 104.67 | -7.24 | -- | -- | -- |
| Nanoform Finland Oyj | 31.30m | -230.57m | 707.63m | 173.00 | -- | 1.50 | -- | 22.61 | -0.2613 | -0.2613 | 0.0354 | 0.5203 | 0.0442 | 80.07 | 9.22 | 16,328.73 | -32.55 | -26.72 | -36.27 | -29.06 | -441.87 | -539.46 | -736.69 | -918.61 | 4.30 | -- | 0.1281 | -- | 8.22 | 124.15 | -12.87 | -- | -1.62 | -- |
| Hamlet BioPharma AB | 0.00 | -56.55m | 729.92m | 6.00 | -- | 18.11 | -- | -- | -0.3157 | -0.3157 | 0.00 | 0.2927 | 0.00 | -- | -- | 0.00 | -95.68 | -78.53 | -104.48 | -91.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.70 | -- | -- | -- |
| Oncopeptides AB | 62.58m | -267.84m | 770.53m | 75.00 | -- | 117.69 | -- | 12.31 | -1.20 | -1.20 | 0.2798 | 0.0253 | 0.2359 | 0.2049 | 1.79 | 782,225.00 | -100.98 | -148.24 | -125.09 | -215.27 | 97.88 | -- | -428.01 | -2,013.60 | 3.27 | -12.10 | 0.9507 | -- | -10.14 | -- | -14.25 | -- | -7.14 | -- |
| Curasight A/S | -63.35m | -68.41m | 981.84m | 4.00 | -- | 39.64 | -- | -- | -1.13 | -1.13 | -1.07 | 0.3809 | -1.52 | -- | -- | -11,171,250.00 | -163.63 | -37.34 | -313.58 | -40.89 | -- | -- | -- | -- | -- | -16.54 | 0.00 | -- | -27.21 | -- | -40.76 | -- | -- | -- |
| Nykode Therapeutics ASA | 60.29m | -97.95m | 1.16bn | 62.00 | -- | 1.31 | -- | 19.16 | -0.3093 | -0.3093 | 0.1939 | 2.88 | 0.0494 | -- | 1.91 | 461,762.70 | -8.03 | 2.32 | -8.66 | 2.60 | -- | -- | -162.46 | 8.51 | -- | -- | 0.0284 | -- | -32.73 | -- | -10.43 | -- | -1.35 | -- |
| XSpray Pharma AB (publ) | 0.00 | -216.42m | 1.16bn | 26.00 | -- | 1.81 | -- | -- | -5.96 | -5.96 | 0.00 | 15.37 | 0.00 | -- | -- | 0.00 | -29.09 | -23.48 | -30.93 | -25.08 | -- | -- | -- | -- | 5.93 | -18.44 | 0.1883 | -- | -- | -- | -58.92 | -- | -14.46 | -- |
| Cantargia AB | 308.69m | 139.93m | 1.30bn | 23.00 | 10.30 | 4.36 | 9.05 | 4.20 | 0.5068 | 0.5068 | 1.33 | 1.20 | 1.41 | -- | 164.02 | 14,031,360.00 | 63.91 | -56.56 | 80.65 | -63.93 | -- | -- | 45.33 | -- | -- | 76.55 | 0.00 | -- | -- | -- | 42.27 | -- | -- | -- |
| Nightingale Health Oyj | 49.70m | -195.50m | 1.44bn | 100.00 | -- | 1.53 | -- | 29.04 | -0.3052 | -0.3052 | 0.0778 | 1.10 | 0.0568 | 0.9444 | 2.79 | 46,930.00 | -22.33 | -15.66 | -24.26 | -16.95 | 75.39 | 75.21 | -393.39 | -447.17 | 8.52 | -- | 0.0511 | -- | 7.69 | 21.38 | -5.71 | -- | -12.69 | -- |
| Solar Foods Oyj | 202.37k | -112.94m | 1.49bn | 57.00 | -- | 6.61 | -- | 7,349.74 | -0.433 | -0.433 | 0.0008 | 0.7115 | 0.0004 | -- | 0.0037 | 455.00 | -22.45 | -- | -27.05 | -- | 25,931.57 | -- | -55,808.37 | -- | -- | -7.03 | 0.5092 | -- | 275.15 | -- | -22.57 | -- | -- | -- |
| Intellego Technologies AB | 770.81m | 294.66m | 1.55bn | 65.00 | 4.75 | 2.33 | 4.81 | 2.01 | 9.81 | 9.81 | 25.91 | 20.01 | 1.28 | 10.59 | 2.32 | 12,432,400.00 | 49.11 | 17.13 | 61.64 | 23.87 | 70.97 | 58.82 | 38.23 | 21.32 | 4.11 | 5.35 | 0.0617 | -- | 42.25 | 222.71 | 14.78 | -- | -- | -- |
| Thor Medical ASA | 93.93k | -55.33m | 1.70bn | 13.00 | -- | 3.77 | -- | 18,093.33 | -0.223 | -0.223 | 0.0004 | 1.36 | 0.0002 | -- | 0.0078 | 11,111.11 | -13.37 | -59.74 | -13.90 | -81.16 | -- | -- | -58,908.00 | -- | 8.78 | -- | 0.018 | -- | -- | -- | -659.00 | -- | -33.37 | -- |
| BioInvent International AB | 244.85m | -323.94m | 1.71bn | 124.00 | -- | 2.50 | -- | 6.97 | -4.91 | -4.91 | 3.72 | 10.38 | 0.2614 | -- | 4.90 | 2,147,790.00 | -34.58 | -19.38 | -38.20 | -20.57 | -- | -- | -132.30 | -189.97 | 7.31 | -- | 0.0154 | -- | -37.47 | -13.77 | -29.99 | -- | 21.19 | -- |
| Devyser Diagnostics AB | 242.80m | -25.20m | 1.71bn | 115.00 | -- | 5.01 | 1,220.48 | 7.04 | -1.52 | -1.52 | 14.66 | 20.48 | 0.5262 | 1.40 | 5.53 | 1,839,394.00 | -5.64 | -10.61 | -6.60 | -12.04 | 81.96 | 80.33 | -10.71 | -28.67 | 2.27 | -2.03 | 0.1312 | -- | 28.12 | 27.53 | -14.74 | -- | 52.54 | -- |
Data as of Feb 13 2026. Currency figures normalised to XSpray Pharma AB (publ)'s reporting currency: Swedish Krona SEK
17.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 26 Sep 2025 | 3.71m | 8.89% |
| Tredje AP-fondenas of 26 Sep 2025 | 1.57m | 3.77% |
| Andra AP-fondenas of 26 Sep 2025 | 1.14m | 2.73% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 480.02k | 1.15% |
| SEB Funds ABas of 30 Jan 2026 | 245.46k | 0.59% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 120.47k | 0.29% |
| Skandia Investment Management ABas of 28 Nov 2025 | 73.69k | 0.18% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 12.93k | 0.03% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 8.77k | 0.02% |
More ▼
Data from 30 Nov 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
